The antibiotics R&D effort is broken. Here's one market solution that might fix it
Anyone even slightly familiar with antibiotics R&D over the last 10 years would quickly agree that the system is badly broken.
Big Pharma — with the exception of Roche — largely pulled out of development because the margins are low. The hunt now is for blockbusters. There are plenty of cheap antibiotics to cover most of the market; the niche for new antibiotics remains too small to sustain any major effort needed here. The little biotechs left with the lion’s share find it’s expensive, highly risky and hard to make pay. And that is not a pretty picture.
This article is for premium subscribers only
Upgrade to a premium subscription plan for unlimited access, and join our community of key biopharma players.
